Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

Munir Pirmohamed, Sally James, Shaun Meakin, Chris Green, Andrew K Scott, Thomas J Walley, Keith Farrar, B Kevin Park, Alasdair M Breckenridge

Abstract

Objective To ascertain the current burden of adverse drug reactions (ADRs) through a prospective analysis of all admissions to hospital.

Design Prospective observational study.

Setting Two large general hospitals in Merseyside, England.

Participants 18 820 patients aged >16 years admitted over six months and assessed for cause of admission.

Main outcome measures Prevalence of admissions due to an ADR, length of stay, avoidability, and outcome.

Results There were 1225 admissions related to an ADR, giving a prevalence of 6.5%, with the ADR directly leading to the admission in 80% of cases. The median bed stay was eight days, accounting for 4% of the hospital bed capacity. The projected annual cost of such admissions to the NHS is £466m (€706m, $847m). The overall fatality was 0.15%. Most reactions were either definitely or possibly avoidable. Drugs most commonly implicated in causing these admissions included low dose aspirin, diuretics, warfarin, and non-steroidal anti-inflammatory drugs other than aspirin, the most common reaction being gastrointestinal bleeding.

Conclusion The burden of ADRs on the NHS is high, accounting for considerable morbidity, mortality, and extra costs. Although many of the implicated drugs have proved benefit, measures need to be put into place to reduce the burden of ADRs and thereby further improve the benefit:harm ratio of the drugs.

Introduction

Lazarou and colleagues suggested that adverse drug reactions (ADRs) caused over 100 000 deaths in the United States in 1994.1 However, this study was criticised for various reasons, including that the death rate was extrapolated from admission rates in 1994, yet based on rates of ADRs taken from studies conducted before 1981.2 Publication bias may have also contributed to what many investigators regard as inflated mortality data.

There are few recent data on epidemiology of ADRs.3 In the United Kingdom, most studies were performed 10 to 30 years ago and were relatively small, often confined to individual units such as for care of the elderly.4 5 The largest UK study was based on retrospective review of case notes,6 and, given the poor documentation of ADRs in medical case notes, it probably underestimated the impact. Of the two most recent UK studies, one concentrated on an acute medical admissions unit,7 while another had broad inclusion criteria for drug related admissions, including overdoses.8 9 Given the changes in medical practice over the past two decades, more recent estimates of the burden of ADRs on hospitals are needed. We undertook a prospective analysis of admissions caused by ADRs in two large UK hospitals to define prevalence and outcome and to assess causality and preventability.

Methods

The study was conducted from November 2001 to April 2002 in two NHS hospitals in Merseyside: hospital A—a teaching hospital serving a population of 300 000—and hospital B—a district general hospital, serving a population of 330 000. To ensure that there was consistency between the two sites, in hospital B, we excluded patients aged <16 years and women presenting with obstetric or gynaecological complaints.

We assessed every patient aged over 16 years who was admitted over the six month period to determine if the admission had been caused by an ADR. Most patients were admitted through either the accident and emergency department or the acute medical and surgical assessment units. The definition of ADR used was that of Edwards and Aronson.10 11 We did not include any patients with either deliberate or unintentional overdose or those who relapsed because of non-compliance. Patients were categorised as having an ADR by either SM (in hospital A) or SJ (in hospital B) if the cause of admission was consistent with the known adverse effect profile of the drug (according to the British National Formulary), if there was temporal relation with the start of drug therapy, and if, after appropriate investigations, other causes were excluded. When the drug history was unclear, we interviewed the patients or relatives or obtained further details from the general practitioner. All patients initially categorised as having an ADR were assessed again by two or
three of the authors, who met to reach a consensus decision and exclude doubtful cases (n = 30, 2.4%). MP undertook a further review of all ADR cases to ensure correct categorisation. Assessment of causality was also performed for all cases using the methods of Naranjo et al.17 and Jones.18 To ensure that patients with ADRs had not been missed, from each hospital we analysed 200 random case notes (400 in total) of patients categorised as not having had an ADR. All assessments were performed by staff with training in drug safety, including specialists in clinical pharmacology and general medicine, pharmacy, geriatrics, and nursing.

Where the patient was categorised as having an ADR, we recorded all drug details, the nature of the reaction, the outcome, the total time spent in hospital, and any invasive investigations performed. In addition, we determined the type of ADR (according to the classification of Rawlins and Thompson)19 and whether it was due to an interaction (according to the interactions listed in the summary of product characteristics or relevant literature, or both).

We assessed avoidability of the ADRs using the definitions developed by Hallas et al.,17 as follows:

- Definitely avoidable—the ADR was due to a drug treatment procedure inconsistent with present day knowledge of good medical practice
- Possible avoidable—the ADR could have been avoided by an effort exceeding the obligatory demands of present day knowledge of good medical practice
- Unavoidable—the ADR could not have been avoided by any reasonable means.

### Statistical analysis

Statistical analysis was performed with the StatsDirect statistical software program (version 1.9.8). The results are presented either as medians and interquartile ranges or percentage frequencies and 95% confidence intervals, as appropriate. Statistical analysis was performed with the Mann-Whitney U test for all data, except for proportions, which were analysed by the z test. A P value < 0.05 was regarded as being significant.

### Results

Over six months there were 18,820 admissions (7911 in hospital A; 10,909 in hospital B). Events judged as being due to an ADR caused 1225 (6.5%, 95% confidence interval 6.2% to 6.9%) admissions. Patients admitted with ADRs (median age 76 years, interquartile range 65-83) were significantly older than patients without ADRs (66 years, 46-79; 95% confidence interval for difference 8 years to 10 years, P < 0.0001). The proportion of women in the ADR group (59%) was significantly higher than in the non-ADR group (52%; z = 4.9; 4% to 10%, P < 0.0001). The admission rate for ADR in hospital A (n = 564, 7.1%) was slightly but significantly higher than in hospital B (n = 661, 6.1%; z = 3.0, 0.4% to 1.8%; P = 0.003). Eighty percent (n = 980; 78% to 82%) of the ADRs were judged to have been directly responsible for the admission (termed “causal”), while 20% (n = 245, 18% to 22%) were identified through screening (termed “coincidental”), and, although not directly responsible for the admission, may nevertheless have contributed to it. Most ADRs (n = 1161, 95%, 93% to 96%) were classified as type A ADRs, according to the classification of Rawlins and Thompson.20 In our review of 400 admissions categorised as not being related to an ADR we did not identify any misclassified patients, indicating that the proportion of false negatives was probably below 1/133.

We determined avoidability of admissions related to an ADR by the method of Hallas et al.17 Only 340 (28%, 25% to 30%) of the ADR were assessed as unavoidable, while 107 (9%, 7% to 10%) and 773 (63%, 60% to 66%) were classified as “definitely avoidable” and “possibly avoidable,” respectively. Thus, we classified 72% of ADRs as avoidable.

We used two forms of assessment of causality for all admissions categorised as due to an ADR.17 18 Most admissions were classified as “probable” (table 1). There was agreement between the two assessments in 1069 (87%) of the admissions.

Table 2 shows the outcome of the patients admitted with ADRs. Although most patients recovered, 28 (2.3%) died as a direct result of the index ADR (as detailed in either the case notes or on the death certificate). Gastrointestinal bleeding was responsible for 15 (34%) deaths (table 3), while aspirin, in isolation or in combination with other drugs, was implicated in 17 (61%) deaths. ADRs were therefore responsible for the death of 0.15% (0.1% to 0.2%) of all the patients admitted.

Patients admitted with an ADR had a median stay of eight days (interquartile range 4-18 days), and the total bed occupancy in the two hospitals was substantial (table 2). The cost of this at average costs per medical bed day ($228; £343, £414)20 would be €466m ($706m, £847m) a year.

Table 4 lists the drugs implicated in causing ADRs. Non-steroidal anti-inflammatory drugs (NSAIDs) and diuretics were most commonly implicated. Aspirin was the most common drug, implicated in 18% of admissions. In these admissions 162 (74%) patients were taking a dose of 75 mg daily. Gastrointestinal bleeding was the most common adverse effect, occurring in 157 (72%) of all aspirin related admissions.

### Interactions

Interactions were responsible for ADRs in 88 (15.0%, 13% to 19%) and 115 (17.4%, 15% to 21%) of the admissions in hospitals A and B, respectively. Overall, interactions accounted for 16.6% (15% to 19%) of ADRs. Examples of interactions included aspirin with warfarin causing gastrointestinal bleeding, aspirin with other NSAIDs leading to gastrointestinal adverse

### Table 1 Assessment of causality of all admissions related to adverse drug reaction.

<table>
<thead>
<tr>
<th></th>
<th>Naranjo method</th>
<th>Jones method</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Defined</td>
<td>Probable</td>
</tr>
<tr>
<td>Hospital A</td>
<td>4 (0.7)</td>
<td>392 (69.5)</td>
</tr>
<tr>
<td>Hospital B</td>
<td>19 (2.9)</td>
<td>400 (68.1)</td>
</tr>
</tbody>
</table>

### Table 2 Outcome of patients admitted to hospital with adverse drug reaction

<table>
<thead>
<tr>
<th></th>
<th>Hospital A</th>
<th>Hospital B</th>
</tr>
</thead>
<tbody>
<tr>
<td>No (%) who recovered</td>
<td>550 (98.4)</td>
<td>642 (97.1)</td>
</tr>
<tr>
<td>No (%) who died</td>
<td>9 (1.6)</td>
<td>18 (2.9)</td>
</tr>
<tr>
<td>Bed days over six months</td>
<td>760</td>
<td>970</td>
</tr>
<tr>
<td>% bed days over one year</td>
<td>3.5</td>
<td>4.4</td>
</tr>
</tbody>
</table>
Table 3 Details of deaths caused by adverse drug reactions

<table>
<thead>
<tr>
<th>Adverse drug reaction</th>
<th>No (%) of cases</th>
<th>Drugs (No of deaths)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal bleeding</td>
<td>15</td>
<td>Aspirin (8), aspirin and dipyrindamide (2), aspirin and diclofenac (1), aspirin and rofecoxib (1), aspirin and meloxicam (1) aspirin and flurbiprofen (1), diclofenac and prednisolone (1), paracetamol (1), warfarin (1)</td>
</tr>
<tr>
<td>Perforated duodenal ulcer</td>
<td>2</td>
<td>Aspirin and diclofenac (1), diclofenac (1)</td>
</tr>
<tr>
<td>Intracranial haemorrhage</td>
<td>5</td>
<td>Aspirin (2), aspirin and diclofenac (1), aspirin and warfarin (1), warfarin (1)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>5</td>
<td>Enalapril and furosemide (1), spironolactone, furosemide and captopril (1), captopril and bumetanide (1), ramipril (1), co-amilofruse and calcium carbonate (Calcichew) (1), included hypercalcemia</td>
</tr>
<tr>
<td>Lithium toxicity</td>
<td>1</td>
<td>Lithium</td>
</tr>
</tbody>
</table>

Discussion

We have undertaken the largest prospective analysis in the United Kingdom of adverse drug reactions (ADRs) as a cause of admission to hospital. Our data show that up to 6.5% or 5.2% (if the fifth of ADRs detected coincidently are excluded) of all admissions are related to ADRs. This is similar to the 5% estimate based on pooled data from several studies worldwide. Many of the studies included in recent systematic reviews, however, are more than 20 years old, and it is disappointing that the burden of ADRs has not decreased.

Study design—strengths and weaknesses

The advantages of our study over earlier work include the prospective nature and size, which allowed a more accurate recording of both the drug history and symptoms, and the assessment of causality. However, as with any other study of this nature, there is a potential weakness in that assignment of an admission as being related to an ADR is subject to clinical judgment, which may vary between individuals. To overcome this, we assessed all patients at least twice, and we subjected all the cases to two validated assessments of causality, which showed a high degree of agreement. Nevertheless, it is impossible to be absolutely certain of a causal link between a drug and an ADR. For example, with low dose aspirin, up to half of the cases of bleeding may have occurred anyway, irrespective of aspirin use. However, it is important to remember that such figures are derived from population based studies and such assessment is not always possible in individual patients.

Burden of ADRs on bed occupancy and cost

Patients with an ADR stayed a median of eight days. Extrapolating this to the whole NHS bed base in England for patients aged >16 years suggests that at any one time the equivalent of up to seven 800 bed hospitals may be occupied by patients admitted with ADRs. This is higher than the estimate in a recent systematic review (four to six 400 bed hospitals), which was based on shorter hospital stays derived from smaller studies. However, it is important to exercise caution in interpreting this estimate of bed use as it is based on extrapolation from two hospitals to the whole NHS bed base, we were not able to determine the causative fractions for all the implicated drugs, and the estimate does not take into account the bed days saved through the beneficial effects of the drugs.

Our data suggest that admissions related to ADRs cost the NHS up to £466 m annually. Although estimates of costs in the literature vary, on a per capita basis our figure is comparable with the lower estimates from the United States, and also with a total costs estimated in a recent UK systematic review. Further detailed analysis, however, is required to provide more accurate figures.

Drugs implicated in ADRs

Lazarou et al suggested that ADRs, based on a death rate of 0.32%, caused over 100 000 deaths in the United States. This figure was based on a 0.13% incidence of fatal ADRs in patients admitted to hospital, and 0.19% in patients developing an ADR while in hospital.

Table 4 Drugs causing adverse drug reactions

<table>
<thead>
<tr>
<th>Drug group/drug</th>
<th>No (%) of cases</th>
<th>Individual drugs</th>
<th>Adverse reactions</th>
</tr>
</thead>
<tbody>
<tr>
<td>NSAIDs</td>
<td>363 (29.6)</td>
<td>Aspirin (218), diclofenac (52), ibuprofen (34), rofecoxib (33), celecoxib (8), ketoprofen (6) naproxen (5)</td>
<td>GI bleeding, peptic ulceration, haemorrhagic cerebrovascular accident, renal impairment, wheezing, rash</td>
</tr>
<tr>
<td>Diuretics</td>
<td>334 (27.3)</td>
<td>Furosemide (128), bendroflumethiazide (103), bumetanide (43), spironolactone (37), amiloride (19), metolazone (11), indapamide (6)</td>
<td>Renal impairment, hypotension, electrolyte disturbances, gout</td>
</tr>
<tr>
<td>Warfarin</td>
<td>129 (10.5)</td>
<td>—</td>
<td>GI bleeding, haematura, high INR, haemoptysis</td>
</tr>
<tr>
<td>ACE inhibitors/</td>
<td>94 (7.1)</td>
<td>Ramipril (28), enalapril (25), captopril (12), lisinopril (9), losartan (6), isosapril (5), perindopril (4)</td>
<td>Renal impairment, hypotension, electrolyte disturbances, angioedema</td>
</tr>
<tr>
<td>All receptor antagonists</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>87 (7.1)</td>
<td>Fluoxetine (17), paroxetine (14), amitriptyline (13), citalopram (9), lithium (8), venlafaxine (8) dosulepin (7)</td>
<td>Confusion, hypotension, constipation, GI bleed, hypoaesthesia</td>
</tr>
<tr>
<td>β blockers</td>
<td>83 (6.8)</td>
<td>Atenolol (69), propranolol (6), isosapril (3), bisoprolol (2), metoprolol (2), carvediol (1)</td>
<td>Bradycardia, heart block, hypotension, wheezing</td>
</tr>
<tr>
<td>Opiates</td>
<td>73 (6.0)</td>
<td>Mepiphan (20), dihydrocodeine (20), co-codamol (8), tramadol (8), co-dydramol (6), fentanyl (6)</td>
<td>Constipation, vomiting, confusion, urinary retention</td>
</tr>
<tr>
<td>Digoxin</td>
<td>36 (2.9)</td>
<td>—</td>
<td>Symptomatic toxic digoxin levels</td>
</tr>
<tr>
<td>Prednisolone</td>
<td>31 (2.5)</td>
<td>—</td>
<td>Gastritis, GI bleeding, hyperglycaemia, osteoporotic fracture</td>
</tr>
<tr>
<td>Diazepam</td>
<td>29 (2.4)</td>
<td>—</td>
<td>GI bleeding</td>
</tr>
</tbody>
</table>

GI=gastrointestinal, INR=international normalised ratio.
hospital. Our analysis of hospital admissions related to ADRs suggests a 0.15% incidence of fatal ADRs, similar to the US figure. More recent data are needed to determine the prevalence of ADR after admission to hospital. In 2002 in England there were a total of 3.8 million acute admissions, suggesting that ADRs causing hospital admission are responsible for the death of 5700 patients (3800 to 7600) every year. The true rate of death taking into account all ADRs (those causing admission, and those occurring while patients are in hospital) may therefore turn out to be greater than 10 000 a year.

Aspirin was identified as a causal agent in 18% of cases of all admissions for ADRs, while other NSAIDs and diuretics were implicated in 12% and 27%, respectively. This is consistent with results of previous studies. The finding that low dose aspirin was the most common drug implicated is relatively novel. However, caution has to be exercised in interpreting these data for two reasons: firstly, we do not have consumption data for these drugs, and the rank order of the implicated drugs may be a reflection of how commonly they are used. Secondly, we have concentrated on harms and have not taken into account the benefits of the drugs. This may be particularly true for drugs such as low dose aspirin, for which convincing data exist of the long terms benefits of prophylactic use in high risk patients. Nevertheless, measures that can further improve the benefit:harm ratio and avoid some of these ADRs need to be put into place. Our data would suggest that over 70% of the ADRs in this study were either possibly or definitely avoidable. Although we have used a previously described method, its weakness is that it does require a degree of clinical judgment, which may have differed with other investigators. Nevertheless, it is consistent with recent data from France and the United Kingdom, which showed that 80% and 67% of ADRs, respectively, were preventable. It is also compatible with a recent meta-analysis, where the rate of preventable ADRs was 59% (interquartile range 50-73%).

Improving benefit:harm ratio

Given our findings and those in the literature, it is therefore incumbent on prescribers to determine the need for a particular drug in a patient and to use this drug at the lowest dose necessary to achieve benefit. Indeed, Langman has calculated that deaths related to aspirin could be reduced by 30% with the lower dose of 75 mg. However, even this dose can result in substantial morbidity and mortality, and other measures are needed. For example, regular use of proton pump inhibitors or misoprostol may be a cost effective method of reducing gastrointestinal adverse events associated with NSAIDs. Given that elderly people seem to be at higher risk of ADRs, many of the recommendations in the National Service Framework for the elderly need to be implemented. Simple measures such as regular review of prescriptions, the use of computerised prescribing, and the involvement of pharmacists in assessing prescribing behaviour may all reduce the burden caused by ADRs. In this respect, it is important to highlight that interactions accounted for one in six of the ADRs in this study.

In conclusion, ADRs are an important cause of hospital admissions, resulting in a considerable use of the NHS bed base, and a significant number of deaths. Many may be preventable through simple improvements in prescribing. We concentrated on ADRs causing hospital admissions and did not evaluate the burden caused by ADR occurring while patients are in hospital, or ADRs in primary care that did not result in hospital admission, which may at least double the figures presented here. Measures are urgently needed to reduce the burden on the NHS.

We thank June Raine (MHRA) for her encouragement and assistance with this study, all staff in both hospitals who assisted with the study, and, in particular, S Roberts, S Morrison-Griffiths, and R Brady for their help in identifying case notes and in data extraction. Contributors: MP, TJW, BKP, and AMB devised the idea of the study, while MP and AMB raised funding. MP oversaw the whole study. SJ and SM collected the data and input the data into databases. AKS, CG, and KF were responsible for study implementation, and review and supervision of the data collection in hospital B. MP and AMB undertook the same roles in hospital A. The analyses were carried out independently by MP and SJ, and verified by TJW. MP produced the first draft, and all authors contributed to the final draft of the manuscript. MP is guarantor for the study.

Funding: The study was funded by the MHRA (Medicines and Healthcare Products Regulatory Agency; formerly the Medicines Control Agency). The MHRA had no role in data interpretation or in the production of this manuscript.

Competing interests: At the time of the study, AMB was chairman of the Committee on Safety of Medicines and now is chairman of the MHRA. MP is a member of the Committee on Safety of Medicines and of the subcommittee on pharmacovigilance. BKP is a member of the Committee on Safety of Medicines.

Ethical approval: Liverpool Local Research Ethics Committee and Wirral Health Authority Research Ethics Committee.
Systematic review of the incidence and consequences of uterine rupture in women with previous caesarean section

Jeanne-Marie Guise, Marian S McDonagh, Patricia Osterweil, Peggy Nygren, Benjamin K S Chan, Mark Helfand

Abstract

Objective To evaluate the incidence and consequences of uterine rupture in women who have had a delivery by caesarean section.

Design Systematic review.

Data sources Medline, HealthSTAR, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, National Centre for Reviews and Dissemination, reference lists, and national experts. Studies in all languages were eligible if published in full.

Review methods Methodological quality was evaluated for each study by using criteria from the United States Preventive Services Task Force and the National Health Service Centre for Reviews and Dissemination. Uterine rupture was categorised as asymptomatic or symptomatic.

Results We reviewed 508 full text articles to identify 71 potentially eligible studies, 21 of which were rated at least fair in quality. Compared with elective repeat caesarean delivery, trial of labour increased the risk of uterine rupture by 2.7 (95% confidence interval 0.73 to 4.73) per 1000 cases. No maternal deaths were related to rupture. For women attempting vaginal delivery, the additional risk of perinatal death from rupture of a uterine scar was 1.4 (0 to 9.8) per 10 000 and the additional risk of hysterectomy was 3.4 (0 to 12.6) per 10 000. The rates of asymptomatic uterine rupture in trial of labour and elective repeat caesarean did not differ significantly.

Conclusions Although the literature on uterine rupture is imprecise and inconsistent, existing studies indicate that 570 (213 to 1370) elective caesarean deliveries would need to be performed to prevent one symptomatic uterine rupture.

Introduction

In the past 20 years, trial of labour has been encouraged for women who have had a caesarean delivery. Recent studies reporting that mother and


6 Hurwitz N. Admissions to hospital due to drugs. BMJ 1965;i:539-40.

7 Hurwitz N. Predisposing factors in adverse reactions to drugs. BMJ 1965;i:769-70.


